[Intravitreal bevacizumab for neovascular age-related macular degeneration].
The efficacy and safety of the therapeutic anti-VEGF concept has already been demonstrated for pegaptanib and ranibizumab. Bevacizumab acts as an antibody against all VEGF-A isoforms and has been developed for oncological indications with intravenous application. Initial reports on intravitreal administration in patients with neovascular age-related macular disease (AMD) have shown beneficial morphological and functional effects. In the meantime, bevacizumab has been used off-label in thousands of patients with AMD. However, data from prospective, controlled, randomized trials on both safety and efficacy are lacking. Herein recent experiences with bevacizumab are summarized and discussed. Furthermore, a web-based platform for online data registration and pooled analyses is presented.
Ladewig
M S
MS
Augenklinik, Universität, Ernst-Abbe-Strasse 2, 53127 Bonn.
Ziemssen
F
F
Jaissle
G
G
Helb
H-M
HM
Scholl
H P N
HP
Eter
N
N
Bartz-Schmidt
K U
KU
Holz
F G
FG
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004348:Drug Labeling; D019317:Evidence-Based Medicine; D006801:Humans; D015552:Injections, Intralesional; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy*; D010818:Practice Patterns, Physicians'; D016896:Treatment Outcome; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab